Lung Cancer Update, Issue 3, 2016 (Video Program) - Video 31Lung Master Protocol (SWOG-S1400) evaluating biomarker-targeted second-line therapy for recurrent Stage IV squamous cell lung cancer
2:27 minutes.
TRANSCRIPTION:
DR BLUMENSCHEIN: So the Master Protocol is a national effort. It’s a cooperative group trial, incorporating many sites, which is trying to identify activating mutations for which we have compounds. So patients will have their tumor profiled. And then, for those patients for whom we have a therapy, whether it’s PI3K or FGFR or CDK, they’re randomized to that arm for therapy. For those patients who don’t have an activating mutation or a druggable mutation, or we don’t have a therapy for that particular mutation, they receive immunotherapy. DR LOVE: Yes. I thought that was really an attractive part of the study because the last I saw it was, I think it was PD-1 versus PD-1 with anti-CTLA-4, which I don’t think you could get that outside a trial setting. DR BLUMENSCHEIN: No, no. I don’t think you can right now. So it’s a good option for folks. DR LOVE: And the other thing that I was seeing on that study that I thought was interesting is, I think right now there are 3 targetable mutations they have with drugs. And they’re finding a fair number of people who have it. So at least it seems like it’s kind of working. And as I mentioned, I don’t know to what extent you were involved with the Battle studies, but to me, that was really the first time that people tried to access tissue specifically to try to target therapy. How do patients respond to this kind of concept? DR BLUMENSCHEIN: Actually, I did participate in the BATTLE trial. I ran one of the arms. And you’re exactly right: This study established that you could, in a metastatic setting, go back and get additional tissue and do the profiling, trying to identify the best therapy for patients. And this was an early effort — this was before we knew about EGFR mutations or ALK translocations — and so we had a series of algorithms that we looked through in terms of what was expressed and trying to determine which of the 4 treatment arms the patient was assigned to. But I can tell you the patients were excited to try something different. There's not a lot of enthusiasm for chemotherapy, although it does work. But patients come looking for something else, and it inherently makes sense to try and do personalized medicine. So I think it’s something that definitely captured patient’s imaginations. So we didn’t have issues with patients wanting to get involved or gain biopsies. |